Physician profile
Daniel Graves
NPI 1255365839
$3,713.70
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832 · 2020: $1,205 · 2021: $1,356 · 2022: $321.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $730.24 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $482.87 | 2019-2022 | |
| Pfizer INC. | $423.03 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $208.10 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $205.73 | 2019-2022 | |
| Amgen INC. | $165.56 | 2019-2021 | |
| Glaxosmithkline, LLC. | $160.79 | 2019-2021 | |
| Novo Nordisk INC | $147.59 | 2019-2022 | |
| Allergan, INC. | $137.01 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $123.30 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $118.44 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.50 | 2019-2021 | |
| Daiichi Sankyo INC. | $96.86 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $81.66 | 2019-2022 | |
| Kyowa Kirin, INC. | $61.97 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $59.73 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.27 | 2020-2022 | |
| Lilly USA, LLC | $54.61 | 2019-2020 | |
| Astellas Pharma US INC | $38.03 | 2019-2020 | |
| Abbott Laboratories | $37.38 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $36.97 | 2019-2020 | |
| Biogen, INC. | $34.27 | 2021 | |
| Eisai INC. | $22.86 | 2020 | |
| Merck Sharp & Dohme LLC | $22.38 | 2021 | |
| Ucb, INC. | $21.09 | 2021 | |
| Horizon Therapeutics Plc | $19.42 | 2019 | |
| Bausch Health US, LLC | $18.95 | 2022 | |
| Acadia Pharmaceuticals INC | $16.10 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.31 | 2021 | |
| Vanda Pharmaceuticals INC. | $12.68 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.